...
首页> 外文期刊>BMC Pulmonary Medicine >Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis
【24h】

Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis

机译:治疗皮质类固醇治疗纤维化超敏肺炎的疗效:倾向分数匹配队列队列分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Fibrotic hypersensitivity pneumonitis (HP) is a chronic interstitial lung disease caused by allergic responses to repeated exposures to a causative antigen. Therapeutic evidence of the use of corticosteroids to treat fibrotic HP remains lacking, although corticosteroids are recognized as a major treatment option. The purpose of this study was to evaluate the efficacy of corticosteroid treatment in patients with fibrotic HP in a propensity score-matched cohort. A retrospective review of the medical records from 2005 to 2019 in a single center was conducted, and 144 patients with fibrotic HP were identified. Semiquantitative scores for lung abnormalities on HRCT were evaluated. Patients who received (PDN group) and did not receive (non-PDN group) corticosteroid treatment were matched using a propensity score method. Survival rates, serial changes in pulmonary function and annual changes in HRCT scores were compared in the matched cohort. In the matched analysis, 30 individuals in the PDN group were matched with 30 individuals in the non-PDN group, the majority of whom had ILD without extensive fibrosis. The survival rate was significantly better in the PDN group (P?=?0.032 for the stratified Cox proportional hazards model; HR, 0.250). The absolute changes in FVC at 6, 12, and 24?months from baseline were significantly better in the PDN group. Fewer patients in the PDN group experienced annual deterioration, as reflected in the HRCT score, due to ground-glass attenuation, consolidation, reticulation, traction bronchiectasis and honeycombing. We demonstrated that corticosteroids improved survival and slowed fibrotic progression in a matched cohort, the majority of whom had ILD without extensive fibrosis. Fibrotic HP with less severe fibrosis may benefit from corticosteroid treatment. We propose that the early initiation of corticosteroids should be considered for fibrotic HP when worsening fibrosis is observed.
机译:纤维化过敏肺炎(HP)是一种慢性间质性肺病,由过敏反应对致病性抗原的反复曝光引起。虽然皮质类固醇被认为是主要的治疗选择,但仍然缺乏治疗皮质类固醇治疗纤维化汞的治疗证据仍然缺乏。本研究的目的是评估皮质类固醇治疗在纤维化HP患者中的患者的患者匹配匹配的队列。对2005年至2019年的医疗记录进行了回顾性审查,在单一中心进行了一次,并确定了144例纤维化HP患者。评估了HRCT对HRCT肺异常的半定量评分。接受(PDN组)并未接受的患者(非PDN组)皮质类固醇处理与倾向得分法匹配。竞争队列比较了肺功能的持续变化和HRCT分数的序列变化。在匹配的分析中,PDN组中的30个个体与非PDN组中的30个个体相匹配,其中大多数没有大量纤维化。 PDN组中存活率显着更好(P?= 0.032,用于分层的Cox比例危险模型; HR,0.250)。 PDN组中,FVC在6,12和24的绝对变化在基线中显着更好。由于地面玻璃衰减,固结,网状化,牵引支气管扩张和蜂窝,PDN组中的患者较少的患者经历了年度恶化,每年都在HRCT得分中反映。我们证明皮质类固醇在匹配的队列中提高了生存和放缓的纤维化进展,其中大多数没有广泛纤维化。具有较小纤维化的纤维化HP可能会受益于皮质类固醇治疗。我们提出,在观察到恶化的纤维化时,应考虑对皮质类固醇的早期开始。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号